Phacilitate is the world’s largest advanced therapies partnering event, bringing together experts and solution providers from all over the world to create the perfect opportunity to network, learn, and be inspired. Brian Hampson, Vice President of Hitachi Chemical Advanced Therapeutics Solutions, had this to say about the Phacilitate 2019 event:
Having been involved in cell therapy before it was even called that, it is incredibly exciting to now see commercialized cell and gene therapies that are literally saving lives and witness the rapid global growth of the industry. From the few hundred participants when I first attended Phacilitate a decade ago to over 1,600 this year, the conference continues to provide a valuable and eclectic mix of coverage including science, technology, clinical, regulatory, manufacturing, business, etc.
Phacilitate continues to provide invaluable insights into the cell and gene therapy industry. Some of the major takeaways from Phacilitate are outlined below:
Key Takeaways from the Conference
The cost-effectiveness of manufacturing and delivering advanced therapeutic products are crucial for long-term success.
Collaboration across the advanced therapies industry is a necessity to overcome the industry’s major challenges and accelerate the application of cell and gene therapies.
Automation is essential to drive the success of the industry.